Work

Phase 1b/2 study to assess the clinical effects of BGB-290 in combination with radiation therapy (RT) and/or temozolomide (TMZ) in patients with first-line or recurrent/refractory glioblastoma

Year: 2017

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx367.054

Authors: P.Y. Wen, K. Shih, D. Schiff, R. Brachmann, R. Weitzman, T. Cloughesy

Institutions: Harvard University, Dana-Farber Cancer Institute, Sarah Cannon, University of Virginia Health System, University of California, Los Angeles

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Eli Lilly and Company, Astellas Pharma

OpenAlex ID: W2761248578

FWCI:

Cites:

Cited by:

Related to: 10